Table 2.
Relationship between different clinicopathological characteristics and prognosis
| Clinicopathological characteristics |
FGFR4 positive |
FGFR4 negative |
χ2 | P value | ||
| Median survival time (mo) | 5-yr survival rate | Median survival time (mo) | 5-yr survival rate | |||
| Gender | ||||||
| Male | 27 | 27.4 | 47 | 36.7 | 1.1198 | 0.2900 |
| Female | 43 | 42.2 | 46 | 44.8 | 0.0000 | 0.9967 |
| Age (yr) | ||||||
| < 60 | 31 | 23.9 | 35 | 30.0 | 0.4080 | 0.5230 |
| ≥ 60 | 44 | 36.1 | 52 | 46.0 | 0.6206 | 0.4308 |
| Tumor size | ||||||
| ≤ 3 cm | 42 | 40.4 | 60 | 69.0 | 5.5033 | 0.0190 |
| > 3 cm | 22 | 24.8 | 24 | 26.2 | 0.0746 | 0.7848 |
| Tumor location | ||||||
| U | 18 | 31.1 | 38 | 31.4 | 0.7164 | 0.3973 |
| M | 43 | 31.5 | 46 | 38.1 | 0.0225 | 0.8807 |
| L | 35 | 29.1 | 52 | 42.5 | 1.1274 | 0.2883 |
| Tumor differentiation | ||||||
| Poor | 17 | 23.4 | 35 | 20.1 | 2.2622 | 0.1326 |
| Well | 31 | 47.0 | 56 | 62.1 | 7.9757 | 0.0047 |
| TNM stages | ||||||
| I + II | 56 | 57.7 | 60 | 69.6 | 1.3128 | 0.2519 |
| III + IV | 15 | 3.5 | 19 | 10.6 | 0.5328 | 0.4654 |
| T | ||||||
| T1 + T2 | 54 | 55.8 | 60 | 82.1 | 4.8827 | 0.0271 |
| T3 + T4 | 22 | 19.4 | 18 | 21.3 | 0.0479 | 0.8268 |
| N | ||||||
| N0 | 58 | 67.4 | 60 | 75.0 | 0.4856 | 0.4859 |
| N1 + N2 + N3 | 18 | 10.1 | 25 | 24.3 | 2.5385 | 0.1111 |
| M | ||||||
| 0 | 43 | 35.3 | 52 | 45.4 | 1.2078 | 0.2718 |
| 1 | 9 | 0.0 | 12 | 0.0 | 0.4042 | 0.5249 |
| Neural I invasion | ||||||
| Yes | 19 | 38.9 | 56 | 18.8 | 2.1949 | 0.1385 |
| No | 36 | 30.2 | 49 | 43.3 | 3.1118 | 0.0777 |
| Vascular I invasion | ||||||
| Yes | 21 | 13.8 | 22 | 14.3 | 0.0507 | 0.8219 |
| No | 42 | 34.0 | 54 | 46.2 | 1.7283 | 0.1886 |
FGFR4: Fibroblast growth factor receptor 4; TNM: Tumor-node-metastasis.